A 63-year-old cancer patient died after he was prescribed too much morphine in hospital. Paulino Amico’s death was hastened ...
Hassan, recently directed a Bengaluru-based hospital and its two doctors to pay Rs 30 lakh compensation to the family of ...
15hon MSN
'Indicator of something serious': Patients warned to keep a close eye on the colour of their pee
A leading pharmacist has urged patients to keep a close eye on the colour of their urine, which can provide vital clues to ...
Alexion’s Koselugo approved in US for adults with neurofibromatosis type 1: Cambridge, UK Friday, November 21, 2025, 09:00 Hrs [IST] Alexion, AstraZeneca Rare Disease’s Koselu ...
Life is Wisdom on MSN
Beyond the Bloat: How Two Young Women's Battles with Ovarian Cancer Highlight Critical Lessons for Early Detection and Self-Advocacy
In the complex landscape of women’s health, ovarian cancer often carries a shroud of misconception, frequently labeled a ...
Dear Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties : As we prepare to end 2025, we would like to provide you with this open letter summarizing our ...
Money Talks News on MSN
Power Peeing and Straining Could Harm Your Pelvic Floor, Doctors Say
Doctors warn that common peeing habits like straining or rushing can weaken pelvic muscles and cause long-term bladder ...
Carle Health Urologist, Dr. Robert Lai, discussed Overactive Bladder (OAB) during Overactive Bladder Awareness Month.
About a year ago, a test revealed that I had an 8-mm stone in my kidney. My kidney doctor was not worried about it. I have ...
AstraZeneca’s Alexion division has received FDA approval for Koselugo (selumetinib) to treat adults with NF1 who have symptomatic, inoperable plexiform neurofibromas. The decision is based on strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback